GlassScriptPhysician profile
Joseph Smotkin
NPI 1376504415
$2,745.48
in general payments reported to CMS, 2019-2025
18 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $446 · 2021: $398 · 2022: $358 · 2023: $228 · 2024: $394 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,042.39 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $547.99 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.77 | 2022-2024 | Jardiance |
| Abbvie INC. | $145.02 | 2021-2024 | Teflaro |
| Alexion Pharmaceuticals, INC. | $140.56 | 2019-2025 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.91 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $103.92 | 2019-2021 | |
| Pfizer INC. | $86.95 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.84 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $60.94 | 2022 | |
| Gilead Sciences, INC. | $55.77 | 2024 | |
| Merck Sharp & Dohme LLC | $37.94 | 2019 | |
| Vapotherm INC | $36.91 | 2020 | |
| Shionogi INC | $33.92 | 2024 | Fetroja |
| Glaxosmithkline, LLC. | $33.30 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.05 | 2019 | |
| Abbott Laboratories | $16.88 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Smotkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.